User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Current status of insulin degludec in type 1 and type 2 diabetes based on randomized and observational trials.

Primary tabs

download
  • Open access
  • PDF
  • 264.88 K
Preumont, Vanessa [UCL] Buysschaert, Martin [UCL]

Insulin degludec is a new ultra-long-action basal insulin. Using treat-to-target protocols, controlled trials have shown comparable HbA reductions with insulin degludec and comparators in both type 1 and type 2 diabetes. Most studies identify, however, better control of fasting plasma glucose with insulin degludec vs. either insulin glargine U100 or detemir, and all have consistently demonstrated clinically relevant decreases in (nocturnal) hypoglycaemic episodes. These characteristics have provided added therapeutic value for insulin degludec in clinical practice. Thus, the aim of this review is to discuss, within the context of randomized and observational studies, the clinical effects of insulin degludec use in type 1 and type 2 diabetes.

Document type Article de périodique (Journal article) – Synthèse de littérature
Access type Accès libre
Publication date 2020
Language Anglais
Journal information "Diabetes & metabolism" - Vol. 46, no. 2, p. 83-88 (2020)
Peer reviewed yes
Publisher Masson ((France) Paris)
issn 1262-3636
e-issn 1878-1780
Publication status Publié
Affiliations UCL - (SLuc) Service d'endocrinologie et de nutrition
UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition
Keywords Fasting plasma glucose ; HbA(1c) ; Hypoglycaemia ; Insulin degludec ; Insulin glargine U100 ; Insulin glargine U300 ; Type 1 diabetes ; Type 2 diabetes
Links
Bibliographic reference Preumont, Vanessa ; Buysschaert, Martin. Current status of insulin degludec in type 1 and type 2 diabetes based on randomized and observational trials.. In: Diabetes & metabolism, Vol. 46, no. 2, p. 83-88 (2020)
Permanent URL http://hdl.handle.net/2078.1/216014